ES2071288T3 - Vacuna mejorada de conjugado de polisacarido de meningococos. - Google Patents

Vacuna mejorada de conjugado de polisacarido de meningococos.

Info

Publication number
ES2071288T3
ES2071288T3 ES91900142T ES91900142T ES2071288T3 ES 2071288 T3 ES2071288 T3 ES 2071288T3 ES 91900142 T ES91900142 T ES 91900142T ES 91900142 T ES91900142 T ES 91900142T ES 2071288 T3 ES2071288 T3 ES 2071288T3
Authority
ES
Spain
Prior art keywords
reciprovals
coli
antibodies
modified
polysaccharide conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900142T
Other languages
English (en)
Inventor
Harold J Jennings
Francis Michon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Application granted granted Critical
Publication of ES2071288T3 publication Critical patent/ES2071288T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

UN POLISACARIDO DEL GRUPO B DE NEISSERIA MENINGITIDIS (GBMP) MODIFICADO PORQUE TIENE GRUPOS DE N-ACETILO CON RESIDUOS DE ACIDO SIALICO SUSTITUIDOS POR GRUPOS DE N-ACILO QUE PRESENTA UNA RESPUESTA INMUNOLOGICA MAYOR AL MISMO. ADEMAS, LA INDUCCION DE LOS ANTICUERPOS QUE REACCIONAN EN CRUZ CON UN MENINGOCOCO DEL GRUPO B NO MODIFICADO Y CON UN POLISACARIDO CAPSULAR DE E. COLI K1 Y OTRAS CELULAS DE LOS TEJIDOS QUE TIENEN UN EPITOPE EN COMUN SE MINIMIZA. LA CONJUGACION DE LOS POLISACARIDOS MODIFICADOS CON UNA PROTEINA FISIOLOGICAMENTE ACEPTABLE COMO POR EJEMPLO TOXOIDES DE TETANOS INDUCE LA PRODUCCION DE ANTICUERPOS PROTECTORES ESPECIFICOS CON NIVELES INSIGNIFICANTES DE ANTICUERPOS REACTIVOS EN CRUZ DE GBMP, PARA ASI CONSEGUIR UNA PROTECCION CONTRA LAS INFECCIONES CAUSADAS POR LOS MENINGOCOCOS DEL GRUPO B Y LA E. COLI K1.
ES91900142T 1989-12-14 1990-12-13 Vacuna mejorada de conjugado de polisacarido de meningococos. Expired - Lifetime ES2071288T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (1)

Publication Number Publication Date
ES2071288T3 true ES2071288T3 (es) 1995-06-16

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900142T Expired - Lifetime ES2071288T3 (es) 1989-12-14 1990-12-13 Vacuna mejorada de conjugado de polisacarido de meningococos.

Country Status (30)

Country Link
US (3) US5576002A (es)
EP (1) EP0504202B1 (es)
JP (1) JP2637845B2 (es)
KR (1) KR0158436B1 (es)
CN (4) CN1049223C (es)
AR (1) AR243934A1 (es)
AT (1) ATE121947T1 (es)
AU (1) AU641715B2 (es)
BR (1) BR9007917A (es)
CA (1) CA2071811C (es)
CZ (1) CZ283530B6 (es)
DE (1) DE69019164T2 (es)
DK (1) DK0504202T3 (es)
ES (1) ES2071288T3 (es)
FI (2) FI104539B (es)
HR (1) HRP920872A2 (es)
HU (2) HU9201966D0 (es)
IE (1) IE68414B1 (es)
IL (1) IL96676A (es)
IN (1) IN171747B (es)
NO (2) NO305275B1 (es)
NZ (1) NZ236471A (es)
PH (1) PH30305A (es)
PL (2) PL166659B1 (es)
RO (1) RO111416B1 (es)
RU (1) RU2105568C1 (es)
SI (1) SI20008B (es)
WO (1) WO1991008772A1 (es)
YU (1) YU24391A (es)
ZA (1) ZA9010065B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
EP0667787B1 (en) * 1992-09-24 2001-07-18 Brigham And Women's Hospital Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
TR199701547T1 (xx) * 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
ES2166097T5 (es) * 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
WO1998058670A1 (en) 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
ATE421527T1 (de) 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
KR100757630B1 (ko) 1997-12-23 2007-09-10 박스터 헬쓰케어 에스.에이. 신규한 추출 및 단리 방법으로 수득되는 세균성 캡슐형 다당류
PL346645A1 (en) * 1998-08-19 2002-02-25 North American Vaccine IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
DE69941574D1 (de) * 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
EP1379272B1 (en) 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2616180T3 (es) * 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
RU2364418C2 (ru) * 2002-08-02 2009-08-20 ГлаксоСмитКлайн Байолоджикалз с.а. ВАКЦИННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЛИПОПОЛИСАХАРИДЫ ИММУНОТИПА L2 И/ИЛИ L3, ПРОИСХОДЯЩИЕ ИЗ ШТАММА NEISSERIA MENINGITIDIS IgtB-
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1654290B1 (en) * 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
BRPI0512413A (pt) * 2004-06-23 2008-03-04 Childrens Hosp & Res Ct Oak derivados de polissacarìdeo e usos na indução de uma resposta imune
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
CA2692069C (en) * 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction

Also Published As

Publication number Publication date
CA2071811A1 (en) 1991-06-15
HRP920872A2 (en) 1997-06-30
CN1100656A (zh) 1995-03-29
RO111416B1 (ro) 1996-10-31
KR0158436B1 (ko) 1998-12-01
DE69019164D1 (de) 1995-06-08
CN1049223C (zh) 2000-02-09
DE69019164T2 (de) 1995-09-07
YU24391A (sh) 1995-12-04
HU9201966D0 (en) 1992-10-28
CZ628490A3 (en) 1997-12-17
ZA9010065B (en) 1992-02-26
NO922316D0 (no) 1992-06-12
PL166659B1 (pl) 1995-06-30
US5902586A (en) 1999-05-11
NO305275B1 (no) 1999-05-03
CN1072506C (zh) 2001-10-10
IL96676A (en) 1996-09-12
AU6898791A (en) 1991-07-18
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
PH30305A (en) 1997-02-20
US5576002A (en) 1996-11-19
JP2637845B2 (ja) 1997-08-06
AU641715B2 (en) 1993-09-30
EP0504202B1 (en) 1995-05-03
IE904513A1 (en) 1991-06-19
PL166035B1 (pl) 1995-03-31
RU2105568C1 (ru) 1998-02-27
CN1055541A (zh) 1991-10-23
PL288271A1 (en) 1991-12-16
IN171747B (es) 1992-12-26
WO1991008772A1 (en) 1991-06-27
NO307835B1 (no) 2000-06-05
FI104539B (fi) 2000-02-29
ATE121947T1 (de) 1995-05-15
BR9007917A (pt) 1992-10-20
DK0504202T3 (da) 1995-10-02
FI19991917L (fi) 1999-09-09
CN1036504C (zh) 1997-11-26
JPH05505392A (ja) 1993-08-12
CA2071811C (en) 2003-11-04
IL96676A0 (en) 1991-09-16
EP0504202A1 (en) 1992-09-23
SI20008A (sl) 2000-02-29
HU218146B (hu) 2000-06-28
AR243934A1 (es) 1993-09-30
NZ236471A (en) 1992-10-28
HUT64480A (en) 1994-01-28
CN1100428A (zh) 1995-03-22
US5683699A (en) 1997-11-04
CN1096516A (zh) 1994-12-21
CN1036522C (zh) 1997-11-26
FI19991917A7 (fi) 1999-09-09
IE68414B1 (en) 1996-06-12
NO973311L (no) 1992-08-14
NO922316L (no) 1992-08-14
FI922737A0 (fi) 1992-06-12
CZ283530B6 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
ES2071288T3 (es) Vacuna mejorada de conjugado de polisacarido de meningococos.
Petrovsky Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity
Anderson et al. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.
JP3717511B2 (ja) サポニン−抗原複合物とその用途
ES2166097T3 (es) Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
DE69925187T2 (de) Antigenkonjugate von konservierten Lipooligosacchariden aus gram-negativen Bakterien
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
BR9510263A (pt) Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas
Cryz Jr et al. Safety and immunogenicity of a polyvalentKlebsiella capsular polysaccharide vaccine in humans
ES2059372T3 (es) Conjugados inmunogenos.
MC2178A1 (fr) Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
ES2171418T3 (es) Vacunas contra neisseria meningitidis del grupo c.
ATE120093T1 (de) Meningococcales klasse i-aussenmembranprotein- vakzin.
NO840341L (no) Fremgangsmaate ved fremstilling av koplet h-influensa type b-vaksine
ES2145072T3 (es) Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
FR2388563A1 (fr) Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires
FR2399252A1 (fr) Vaccin de masse moleculaire elevee contre la meningite a meningocoques du groupe c et procede pour sa preparation
ES2051909T3 (es) Vacuna del conjugado de polisacarido-proteina de membrana externa contra la haemophilus influenzae tipo b.
CA2623400C (en) Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni
DE69525638T2 (de) Synthese eines typhusimpfstoffes unter verwendung eines polysaccharids aus einer pflanze oder einer frucht
Trzewikoswki de Lima et al. Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged?
Cabral-Hipólito et al. Tannic acid exhibits adjuvant activity by enhancing humoral and cell-mediated immunity against BSA as a protein antigen
Dzata et al. Immunopotentiation of cattle vaccinated with a soluble Brucella abortus antigen with low LPS content: an analysis of cellular and humoral immune responses
Habel Factors Influencing the Efficacy of Phenolized Rabies Vaccines: I. Strains of Fixed Virus
NO892015D0 (no) Fremgangsmaate for fremstilling av et legemiddel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504202

Country of ref document: ES